




RealRate

PHARMACEUTICAL 2022

Procyon CORP
Rank 168 of 471

PROCYON



The relative strengths and weaknesses of Procyon CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Procyon CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Procyon CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is 333%, being 58% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	2,872
Cost of Goods Sold	1,331
Intangible Assets	17
Liabilities, Current	736
Liabilities, Non-Current	654
Other Assets	1,269
Other Compr. Net Income	0
Other Expenses	1,871
Other Liabilities	0
Other Net Income	507
Other Revenues	4,720
Property and Equipment	109
Research and Development	0
Selling, General and Administrative Expense	1,330

Output Variable	Value in 1000 USD
Assets	4,267
Liabilities	1,389
Expenses	4,532
Revenues	4,720
Stockholders Equity	2,878
Net Income	694
Comprehensive Net Income	694
BaseVar	7,708
ECR before Limited Liability	246%
Economic Capital Ratio	333%